-
Pfizer signs strategic partnership with Ali Health
Time of Update: 2021-03-05
Based on the good foundation and trust before, the two sides also landed in this strategic cooperation Internet physician training public welfare project: inviting experts in various disease fields, using the Mayo Clinic education system and information introduced by Pfizer, to provide Ali Health's Internet physicians with systematic professional academic training to improve their ability to diagnose and treat common diseases such as pediatrics, male reproduction, pain and cardiovascular diseases, so as to better serve patients.
-
Lower drug prices into the main theme of down-to-earth do medicine do not worry about no market
Time of Update: 2021-03-05
to solve the problem of people "expensive to see a doctor", has always been one of the main tasks of the new medical reform, and the price of medicine is inflated, it is the common people "expensive
-
One of the "Big Three" of medical dressings, Omei Medical, is going to land on the A-shares
Time of Update: 2021-03-05
Omei Medical is mainly for international medical device brand manufacturers, such as the United States Johnson and Johnson to provide OEM services, that is, "production." Aomei Medical's IPO plans to raise 598 million yuan, of which 354 million yuan will be used for medical cotton yarn projects and medical gauze projects, the remaining 244 million yuan for medical hygiene non-manufacturing projects.
-
Changfeng Pharmaceuticals completed a 630 million yuan round of E financing for the development of respiratory drugs
Time of Update: 2021-03-05
Prior to this, Changfeng Pharmaceuticals has completed five rounds of financing, Kaifeng Ventures, Yuanyu Origin, Jinpu Investment, Longmen Investment, Yuanming Capital, China Investment Innovation, CCB International and other well-known investment institutions have participated in the investment.
-
The credit is getting the Asia-Pacific Pharmaceuticals subsidiary out of control
Time of Update: 2021-03-05
In the first half of 2019, Asia Pacific Pharmaceuticals achieved net profit attributable to RMB40,239.1 million, compared with RMB41,544.9 million for Shanghai's new peak during the same period.
-
Pharmaceutical mergers and acquisitions boom continues the pharmaceutical industry reshuffle
Time of Update: 2021-03-05
▍ the pharmaceutical industry as early as 2017, the General Office of the State Council issued "on further reform and improvement of drug production and circulation policy." Clearly put forward: " to support the merger and reorganization of pharmaceutical production enterprises, simplify the cross-regional transfer of products within the Group to market approval procedures, cultivate a number of internationally competitive large enterprise groups, improve the concentration of the pharmaceutical industry.
-
From "buy, buy" to "naturalized" listed pharmaceutical companies experienced what?
Time of Update: 2021-03-05
With the promotion of many pharmaceutical industry policies that encourage innovation, such as consistent evaluation of the quality and efficacy of generic drugs, volume procurement, and medical ins
-
The restructuring plan will be pushed back again by the choice of whether to run up to the medical adjustment
Time of Update: 2021-03-05
Looking back at the restructuring plan, Runda Medical intends to buy 70% of Suzhou Run win, 70% of Shanghai Runlin, 25% of Hangzhou Yidan, 60% of Shanghai Weikang and 55% of Shanghai Ruimei by way of issuing shares and paying cash, with a total transaction price of 1,137 million yuan.
-
Will biosynthic drugs impact the diabetes drug industry in the future?
Time of Update: 2021-03-05
Six years after entering China in 2017 through negotiations into the national health care directory, liraglutide in the Chinese market has a relatively significant volume, 2018 sales revenue increased 73% to 521 million Danish kroner (about $82.5 million), has accounted for 87% of China's entire GLP-1 drug market share, but also accounted for only 1.3% of the entire diabetes drug market share.
-
Fissen Technology completed the hundreds of millions of yuan C round of financing led by Sequoia China
Time of Update: 2021-03-05
Domestic digital oral industry leader, digital oral overall solutions provider - Shenzhen Feisen Technology Co., Ltd. (hereinafter referred to as "Fison Technology") recently announced the completio
-
Hengrui lost its 200 billion-dollar market capitalization "share god" pit crying nearly 30,000 shareholders
Time of Update: 2021-03-05
As of the close of trading on December 26, 2018, only Hengrui Pharmaceuticals and Meirui Medical had a market capitalisation of 100 billion, while Shanghai Lais, the former "share god", and Huada Gene, which is second only to Maotai in share prices, seemed to be further away from the market capitalisation of 100 billion yuan.
-
Pharmaceutical Biology: More than 70% of the company's annual report predicts that rigid demand will help the industry grow
Time of Update: 2021-03-05
Among them, the 10 companies of ST Hai investment, Jiaying Pharmaceuticals, Jiuan Medical, Xinhecheng, ST Guanfu, Tiger Pharmaceuticals, Essence Pharmaceuticals, American Health, Sunflower Pharmaceuticals and Foci Pharmaceuticals are expected to achieve a net profit growth rate of 50% or more on a month-on-month basis.
-
Greenlee Pharmaceuticals has teamed up with AstraZeneta to advance its cardiovascular business
Time of Update: 2021-03-05
the evening of January 15, Greenlee Pharmaceuticals, a Hong Kong-listed company, announced that it would grant AstraZene the right to promote the group's first-line lipid management drug, Lipid Kang capsules, at Chinese mainland.
-
Nanoview completed the 160 million yuan B round of financing led by Sherba
Time of Update: 2021-03-05
"This round of financing is led by Sherba, and the funds are planned for the commercialization of products," said Li Yunxiang, CEO of Nanoview.
Comprehensive estimates, China's CT equipment sales market size will be at least 20 billion yuan.
-
Fairy fight, enterprise suffered domestic generic drugs in the future has a long way to go
Time of Update: 2021-03-05
on this matter, deconstructed as follows: the variety of "Chinese Pharmacopoeia" all specifications (0.125g, 0.25g and 0.5g specifications) solubility inspection is proposed as: basket method / 100 turn, water medium 900ml, 45min, 80% limit.
-
The second round of volume procurement fire has been burned to self-cost medicine
Time of Update: 2021-03-04
In addition to Acapo sugar and solana, Adelfovesters, tadalaf and Allison Tan are all self-cost drugs, meaning that the war on volume purchases has spread above the price of medicines outside the National Health Insurance Directory.
-
Lepu Healthcare made a net profit of $1.2 billion from strong sales of bio-absorbable stents
Time of Update: 2021-03-04
the reasons for the first-half 2019 results growth, Lepu Medical said in a statement that its newly developed NeoVas bio-absorbable support, or NeoVas, has been contributing strong new earnings growth since it went on sale in late March.
-
Fist products 50 million yuan transfer into the pharmaceutical industry or for the turnaround?
Time of Update: 2021-03-04
Shenzhen Stock Exchange issued a letter of concern to this, asking the dual-form pharmaceutical industry to explain the production and sales since the "Drug GMP Certificate" obtained in May this year, the specific impact of the relevant technology transfer on the company's performance and the company's proposed response measures.
-
Companies such as Alibaba Cloud have announced advances in the medical layout of artificial intelligence
Time of Update: 2021-03-04
It is understood that Alibaba Cloud joint ecological partners from storage, sharing to intelligence, to provide cloud-to-cloud integrated image cloud solutions, can provide a large number of secure storage services, digital images can automatically multi-redundant backup, real-time access to historical images, interregional image connectivity, and so on.
-
Seventy percent of enterprises or eliminated injection consistency evaluation is faced with three options
Time of Update: 2021-03-04
Those enterprises with the integration of raw material preparations, although there are not many varieties of consistent evaluation drugs, will still have significant advantages in the future competition.
